The Hepatitis C Virus (HCV) is estimated to infect about 3% of the world population with chronic infections resulting in liver fibrosis, cirrhosis and hepatocellular carcinoma. Though culturing of the virus was a big challenge; the whole genome could be deciphered through many molecular biology techniques. The treatment of HCV through antivirals and later in combination with interferons produced considerable toxicity. However, with the development of directly acting antivirals (DAA), in recent years, has shown good control of HCV. The use of DAAs in the treatment regimen of HCV has been a game changer, as vaccine is not yet available.